Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.5400 (1.28%) ($5.4600 - $5.6200) on Mon. Feb. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.27% (three month average) | RSI | 39 | Latest Price | $5.5400(1.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.7% a day on average for past five trading days. | Weekly Trend | ADMS declines -1.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(20%) TBT(12%) UUP(8%) KWEB(6%) IBB(5%) | Factors Impacting ADMS price | ADMS will decline at least -3.635% in a week (0% probabilities). PCY(-21%) BWX(-21%) BNDX(-18%) EMHY(-17%) BND(-16%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.635% (StdDev 7.27%) | Hourly BBV | 0 () | Intraday Trend | 1.5% | | | |
|
5 Day Moving Average | $5.55(-0.18%) | 10 Day Moving Average | $5.4(2.59%) | 20 Day Moving Average | $5.54(0%) | To recent high | -24.1% | To recent low | 8.6% | Market Cap | $157m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |